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Abstract 
Background & Aims : We studied impaired quality of life (QOL) and its determinants 
among individuals with nonalcoholic fatty liver disease (NAFLD). 
Methods : We collected data from 341 patients with NAFLD who completed the short 
form 36 (SF-36) questionnaire. Body composition and liver fibrosis were assessed in 
patients with NAFLD using bioelectrical impedance and transient elastography, 
respectively. Advanced fibrosis was defined as liver stiffness measurements (LSMs) of 
12.1 kPa or greater. SF-36 scores of patients with NAFLD were compared with SF36 
scores of individuals with chronic medical illnesses and the general population obtained 
from the published literature. 
Results : Among patients with NAFLD, percent body fat was negatively associated with 
scores from all 8 SF-36 scales, whereas lean body mass was positively associated with 
scores from 5 of 8 SF-36 scales. On multivariable analysis, SF-36 PF scores were 
negatively associated with type 2 diabetes, body mass index, and LSM and positively 
associated with lean body mass and level of alanine aminotransferase. Patients with 
NAFLD, and even those without advanced fibrosis, had significantly lower mean QOL 
scores than the control group or the general population. 
Conclusions : Individuals with NAFLD, even those without advanced fibrosis, have 
lower QOL than controls. Body composition associates with QOL in patients with 
NAFLD; both of the modifiable factors independently associated with QOL are related to 
body composition. Further studies are needed to investigate if interventions to improve 
body composition can increase QOL for patients with NAFLD. 
 
Keywords : BMI, overweight, obesity, steatosis  




Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver 
disease in the US and it is rapidly becoming one of the leading causes for liver related 
morbidity and mortality. 1–3  There is growing interest in better understanding the 
relationship between NAFLD and patient reported outcomes such as quality of life 
(QOL). Over the last decade, a number of studies have emerged in the literature 
describing reduced QOL in patients with NAFLD. 4–6  While these studies significantly 
advanced our understanding of QOL in NAFLD and NASH, they have largely included 
select subgroups of patients (e.g., biopsy proven NASH) participating in randomized 
clinical trials or observational studies. 4–6  These studies have utilized both the Short 
form 36 (SF-36) 4 and the Chronic Liver Disease Questionnaire (CLDQ). 5,6  The CLDQ 
was developed for measuring QOL in patients with various types of chronic liver disease 
and is widely utilized in various research settings. 5,7–9 However, this tool does not allow 
for comparisons to chronic medical conditions other than chronic liver disease or to 
general population.  The SF-36 questionnaire, while not specifically designed for liver 
disease population, has long been used to estimate QOL in many different populations 
and it allows for comparing QOL among different populations including general 
population.10–15    
 
When measuring QOL in patients with NAFLD, it is important to account for the 
impact of coexisting morbidities (e.g., obesity, diabetes, hypertension, etc) on their QOL 
as each of these comorbidities has been associated with reduced QOL. 12,16–24 In this 
regard, it is important to compare the QOL of NAFLD patients to another group of 
individuals without known liver disease but enriched with metabolic comorbidities. In 
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other disease states, it is well recognized that body composition is an important 
correlate for poor quality of life.25–27 There are no studies to date examining the impact 
of body composition on reduced QOL in patients with NAFLD.  
 
To further advance of our understanding of QOL in patients with NAFLD, we 
conducted a prospective, clinic based study of unselected patients with well 
characterized NAFLD to examine the relationship between (a) body composition and 
QOL in NAFLD and (b) QOL and NAFLD-related clinical variables, including liver 
stiffness and fibrosis.  As an exploratory aim, we compared the QOL of this cohort of 
patients with NAFLD to a cohort of patients with chronic medical illnesses and to the 
United States general population.   
 
Methods  
Consecutive patients with NAFLD referred to Indiana University NAFLD Clinic who 
completed SF-36 questionnaire were included in this analysis. This study was approved 
by the Institutional Review Board and all participants signed an informed consent.  
 
The presence of NAFLD was defined based on the AASLD guidelines where there was 
evidence of hepatic steatosis, either by imaging or histology, and lack of secondary 
causes of hepatic fat accumulation such as significant alcohol consumption, long-term 
use of a steatogenic medication, or monogenic hereditary disorders. 28  After enrollment, 
participants were offered to undergo body composition analysis and complete a SF-36 
questionnaire in addition to clinical evaluation, which included laboratories, vibration 
controlled transient elastography (VCTE), and where clinically indicated, a liver biopsy.  
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The SF-36 is a health survey, which measures QOL of individuals equal to or greater 
than 18 years of age, in eight dimensions: physical functioning (PF), role limitations due 
to physical health (RLPF), emotional well-being (EW), role limitations due to emotional 
problems (RLE), energy/fatigue (EF), social functioning (SF), pain, and general health 
(GH). Each scale of SF-36 was transformed to a continuous scale ranging between 0 - 
100, and scores were calibrated in such a way that 50 is the average. 29 SF-36 
questionnaire version 1 was chosen to assess health-related QOL for this study due to 
select strengths of this questionnaire over disease-specific instruments. 30 First, it is 
used widely in the literature in many disease states with well-established interpretive 
methodology and normative data. Second, as one of our primary outcomes was to 
compare how QOL in NAFLD compares to individuals with non-liver related chronic 
medical illnesses, it was crucial to utilize an instrument that was validated in both 
general population and in those with multiple chronic medical illnesses. Lastly, in 
addition to its performance in the general population, metabolic syndrome, chronic 
medical illnesses, SF-36 performed well in the NAFLD population. 31  
 
The SF-36 questionnaires were scored based on their responses, as indicated in the 
RAND webpage. 30 The score for each scale would be the proportion of the total score 
that is possible. Blank items were not taken into account for the total score, and scales 
represent the average of all items answered by individuals. SF-36 scores from 
previously published cohorts with multiple chronic medical illnesses 11 and the general 
population in the United States 29 were used for comparative purposes. The cohort with 
chronic medical illnesses (N = 3445) had mean age of 54 years, 61.7% female, 76.2% 
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White with 52% who graduated from high school, and a minority who were poor (7.3%). 
The chronic medical illness burden of this population included hypertension (60.6%), 
diabetes (18.1%), congestive heart failure (6.3%), myocardial infarction (3.1%), clinical 
depression (14.6%), and symptomatic depression (22.8%). 11 Fibroscan@ Touch 502 
was used to measure liver stiffness measurement (LSM) and continued attenuation 
parameter (CAP) as surrogates for liver fibrosis and liver steatosis, respectively. 
Medium probe was used in 18% and XL probe was used in 82%. A liver biopsy was 
performed where clinically indicated. Among those who had a liver biopsy before 
enrollment in the study, histology slides were requested and reviewed by our dedicated 
liver pathologists. Liver histology was scored based on the NASH CRN scoring 
system.28 
 
The body composition was measured using InBody 570 (InBody, Seoul, Korea), which 
utilizes bioelectrical impedance technology.32 Dry lean mass is a measure of protein and 
mineral content, while lean body mass is a measure of everything in the body except fat 
and includes dry lean mass and total body water. Body fat mass is a measure of total 
body fat (subcutaneous and visceral), and percent body fat is the ratio of body fat mass 
to the total weight. The skeletal muscle mass is the total weight of skeletal muscle.  
 
Statistical Analysis  
Continuous variables were expressed as mean ± Standard deviation or median with 
ranges as appropriate. Categorical variables were expressed as percentages or 
proportions. Comparisons across categories are based on the Chi-square test (or 
Fisher's Exact test) for categorical variables, and comparisons for continuous variables 
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are based on ANOVA or Wilcoxon (Normal Approximation). Pearson correlation 
coefficient was used to analyze correlations between scales of SF-36 and patient and 
disease-specific variables. Univariate analysis was performed to understand the 
relationship between variables and SF-36 scales. Variables that were related to SF-36 
scales at or below p-value of 0.05 were included in multivariable analysis. If multiple 
metabolic syndrome features or multiple co-linear laboratory parameters were 
associated at or below p-value of 0.05, one of the metabolic syndrome features or co-
linear laboratory values were chosen in the multivariable model to minimize multi co-
linearity. We removed variables that had excessive missingness rate. SF-36 scales and 
LSM were analyzed as continuous variables for univariate analysis. Additionally, LSM 
was also categorized into those with and without advanced fibrosis.  Advanced fibrosis 
was defined as LSM > 12.1 kPa, which had 90% specificity for excluding stage 3 and 4 
fibrosis. 33 Radar chart was designed using charts function on excel spreadsheet. 
 
Results 
Three hundred and ninety-eight individuals were enrolled in the study from July 2017 to 
September 2019, of whom 341 participants completed the SF-36 questionnaire. Of 
these, 299 (88%) had transient elastography, 112 (33 %) had a liver biopsy, and 279 
(82%) had body composition analysis. 
 
Baseline characteristics of the NAFLD cohort  
Three hundred and forty-one individuals with nonalcoholic fatty liver disease (NAFLD) 
who completed the SF-36 questionnaire constituted our study cohort. The mean age of 
the cohort was 52.5 years, 96% were White, and 60% were females, 85% were obese, 
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48% had type 2 diabetes, and 55% had hypertension. Median LSM was 8.5 kPa (range, 
2.1 KPa – 75 KPa). Detailed characteristics of the study cohort are listed in Table 1 .  
 
Body Composition and SF-36 
Correlation coefficients between body composition parameters (body mass index (BMI), 
body fat mass, percent body fat, lean body mass, dry lean mass, and skeletal muscle 
mass) and SF-36 scales are listed in Table 2 . Physical and mental summary 
component score were positively correlated with lean body, dry lean and skeletal 
muscle mass. Additionally, physical summary component score was negatively 
correlated with BMI, body fat mass and percent body fat. Individual scales of each 
summary score followed similar trends. Notably, percent body fat was the only variable 
that was significantly negatively associated with all eight scales of SF-36.  
 
Demographic and clinical variables of NAFLD patients associated with SF-36 
scores 
Results from univariate and multivariable analysis of factors associated with the PF 
scale are shown in Table 3 . PF scores were univariately negatively associated with age, 
BMI, type 2 diabetes, hypertension, LSM and, ballooned hepatocytes and fibrosis on 
histopathology, and positively associated with male gender, ALT, and lean body mass. 
On multivariable analysis, type 2 diabetes, LSM, and BMI were negatively associated 
with PF score, whereas ALT and lean body mass were positively associated with PF 
score. Univariate and multivariable analyses of the other seven SF-36 scales are shown 
in Supplementary Table 1 , where we observe general trends of a positive association 
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of male gender and negative association of BMI and LSM with most of the SF-36 
scales. 
 
SF-36 scales in individuals with NAFLD with and without advanced fibrosis 
Characteristics of individuals with NAFLD with and without advanced fibrosis are listed 
in Table 1. The QOL in the NAFLD cohort was significantly different between those with 
and without advanced fibrosis. Details of these differences are shown in Table 4 . SF-36 
scores for PF, RLPF, EW, RLE, and EF were significantly lower among those with 
advanced fibrosis compared to those without advanced fibrosis. When advanced 
fibrosis was defined based on stage 3 and 4 fibrosis on histopathology, similar trends 
were seen. Additionally, SF and pain scores were also significantly lower in those with 
advanced fibrosis. The differences in SF-36 scales based on histopathology are 
detailed in Supplementary Table 2 . 
 
QOL in the subgroup of NAFLD without advanced fibrosis 
The factors associated with SF-36 PF scale in NAFLD without advanced fibrosis are shown in 
Table 5 . The associations with other seven SF-36 scales are listed in Supplementary 
Table 3 .  On univariate analysis, male gender, lean body mass, and ALT were positively 
associated, while age and BMI were negatively associated with the PF scale in the 
subgroup without advanced fibrosis.  Lean body mass, ALT continued to be positively 
associated, and BMI negatively associated with PF scale on multivariable analysis. As 
seen in the entire cohort, age and male gender no longer had significant association on 
multivariable analysis. Among individuals without advanced fibrosis, the LSM or fibrosis 
staging by histopathology were not associated with the SF-36 PF scale.  
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SF-36 scales in the NAFLD cohort compared to chronic medical illness cohort 
and the United States general population  
Details of the chronic medical illness cohort are described in the methods section.  
Figure 1  shows a radar chart of the eight SF-26 scales in the NAFLD cohort compared 
to the chronic medical illness cohort and the US general population. Mean scores of the 
eight scales of SF-36 in the NAFLD cohort, subgroup of NAFLD without advanced 
fibrosis, chronic medical illness, and the general population in the US are listed in 
Supplementary Table 4. NAFLD cohort had significantly low scores across all eight 
scales compared to the US general population and in six of eight scales (PFing, EF, SF, 
pain, and GH and RLE) compared to chronic medical illness cohort. The QOL in the 
subgroup of NAFLD without advanced fibrosis was significantly lower than the US 
general population across all SF-36 scales, except for EW and RLE and significantly 




In this clinic-based study, we confirm that QOL in individuals with NAFLD is significantly 
lower among those with advanced fibrosis. A novel observation of our study is that body 
composition parameters are significantly associated with reduced QOL. In fact, body 
composition parameters are the only two modifiable factors that significantly associated 
with low QOL in NAFLD. Our exploratory analysis shows that QOL in a well-
characterized cohort with NAFLD was not only lower than that reported for the US 
general population but also lower than QOL reported in chronic medical illness cohort. 
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Percent body fat correlated negatively with all SF-36 scales in the NAFLD cohort. Lean 
body mass, dry lean mass, and skeletal muscle positively correlated with PF, RLPF, 
EW, RLE, and SF scales. BMI and body fat mass negatively correlated with PF, RLPF, 
EF, pain, and GH scales.  Lean body mass was significantly positively associated with 
PF score in the NAFLD cohort and the subgroup without advanced fibrosis, after 
adjusting for multiple other factors.  
 
In our study, five of eight SF-36 scales (PF, RLPF, EW, RLE and EF) were significantly 
lower in NAFLD with advanced fibrosis. These findings remained consistent even when 
liver histology was used  for defining advanced fibrosis. These results are different from 
a previously published study in a well-characterized NAFLD cohort, where only PF scale 
was found to be different between those with and without cirrhosis. 4 Our study cohort 
had a high proportion with advanced fibrosis, 34% based on LSM, and also based on 
histopathology (39% vs. 28%), and higher prevalence of comorbidities, such as type 2 
diabetes (48% vs. 27%), compared to previously published study.  
 
After adjustment for other factors, BMI, presence of type 2 diabetes, and LSM were 
negatively, while lean body mass and ALT were positively associated with PF score. 
Previously published studies in the general population reported a negative association 
of BMI 12,16,17,24 and age with the SF-36 PF scale. 34 In the subgroup of patients without 
advanced fibrosis, lean body mass and ALT were positively associated, while BMI was 
negatively associated with the PF score. Although the male gender was positively 
associated with PF score on univariate analysis in the entire cohort and the subgroup 
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without advanced fibrosis, the association lost significance on multivariable analysis 
after adjusting for age, BMI, lean body mass, presence of type 2 diabetes, ALT and 
LSM. Our findings highlight the important role of body composition in influencing QOL in 
individuals with NAFLD. 
 
In our exploratory analysis, we observed that QOL in the NAFLD cohort was 
significantly lower than that reported for the US general population and chronic medical 
illness cohort. These differences were evident even with the subgroup of NAFLD 
without advanced fibrosis.  This was intriguing because chronic medical conditions such 
as obesity and hypertension by themselves are associated with diminished QOL. SF-36 
PF scores were significantly lower in severely obese, obese and overweight (63.5 ± 0.9, 
74.1 ± 0.7, and 80 ± 0.5) compared to normal weight (85.9 ± 0.4) in post-menopausal 
women.13 As a reference, SF-36 PF score in our NAFLD cohort was 68.3 ± 27.8. 
Presence of hypertension reduced QOL (SF-36 PF - 70.9 ± 27.4 vs.89.2 ± 18.6) in the 
Swedish population based study.22 We admit that our control groups likely have 
undiagnosed NAFLD in some proportion, thus making our interpretations challenging.  
 
Several limitations of our study deserve further discussion. While our participants were 
a “real-world” sample of NAFLD patients, they were enrolled at a single tertiary care 
center. Fibrosis in our cohort was determined based on LSM on transient elastography. 
While LSM has been proven to be a valid estimation of liver fibrosis, liver histology was 
only available in 33% of our cohort. Notwithstanding this limitation, our study is one of 
the first studies to evaluate the association between QOL and LSM, which is used more 
commonly in daily practice than a liver biopsy to determine the severity of fibrosis. 
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Another limitation of our study cohort was the lack of diversity, with the majority of 
participants being Caucasian and a small representation from other race and ethnicity 
groups. The clinical relevance of various statistically significant numerical differences 
that we observed in our study is unclear and may be addressed in a larger study 
including individuals with NAFLD, chronic medical illnesses and general population 
where the independent relationship between levels of individual domain score and 
overall well-being can be investiged.  
 
Despite these limitations, our study shows that individuals with NAFLD have poorer 
QOL than the US general population and chronic medical illness cohort and QOL is 
further diminished in NAFLD with advanced fibrosis. Interestingly, even patients without 
advanced fibrosis had worse QOL compared to general population and those with 
chronic medical illnesses, suggesting that factors other than fibrosis are behind their 
lower QOL. We also show that in NAFLD, body composition parameters (BMI and lean 
body mass) are associated with QOL after adjustment for multiple factors and in fact are 
the only two modifiable factors of the five associated with QOL. Further studies are 
needed to investigate if interventions improving the body composition in patients with 
NAFLD would positively impact their QOL.   
 
In summary, in this study we show that (a) patients with NAFLD have worse QOL 
compared to the US general population and those with chronic medical illnesses; (b) 
body composition parameters are significantly associated with QOL in NAFLD and in 
fact they are the only modifiable factors (BMI and lean body mass) associated with QOL 
in this population; and (c) although advanced fibrosis is an important determinant of 
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QOL in patients with NAFLD, interestingly even those without advanced fibrosis had 




Figure 1: Radar chart comparing the eight SF-36 scales of NAFLD cohort with 
chronic medical illness cohort and the US general population. Each spoke 
represents a SF-36 scale (0-100). 
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Table 1: Baseline characteristics of NAFLD cohort and those with and without 
advanced fibrosis  
 
Variables  Overall  





Mean ± SD 
(N=197) 
Advanced fibrosis  
(> 12.1 KPa) 
Mean ± SD 
(N=102) 
P-value¶ 
Age (years) 52.54 ± 13.26 49.79 ± 13.09 55.19 ± 12.30 0.0006 



























Ethnicity: Hispanic, % 2.4 2 3 0.21 
BMI (kg/m2) 36.07 ± 7.21 34.62 ± 6.89 38.28 ± 7.08 <0.0001 




8.5 (5.95 - 16.30) 6.4 (6.0 - 8.5) 20.8 ( 15.2 - 27.9) <0.0001 
Continuous Attenuation 
Parameter (db/m) 
327.81 ± 54.51 320.57 ± 53.61 341.77 ± 53.78 0.001 
Risk Factors Associated with NAFLD     
Obesity, % 85 81 91 0.03 
Type 2 Diabetes mellitus, 
% 
48 38 66 <0.0001 
Dyslipidemia, % 45 43 55 0.06 
Hypertension, % 55 47 69 0.0005 
Obstructive Sleep 
Apnea, % 
26 23 30 0.15 
Hypothyroidism, % 13 12 15 0.53 
Laboratory Data     
ALT (U/L) 46.94 ± 35.83 48.49 ± 34.57 47.93 ± 41.42 0.90 
AST (U/L) 38.27 ± 23.00 35.47 ± 22.55 43.37 ± 24.56 0.01 
ALP (U/L) 84.03 ± 44.81 80.33 ± 47.23 82.03 ± 30.8 0.75 
Total Bilirubin (mg/dl) 0.75 ± 0.58 0.65 ± 0.37 0.79 ± 0.74 0.04 
Total Protein (gm/dl) 7.40 ± 0.49 7.45 ± 0.45 7.34 ± 0.51 0.06 
Albumin (gm/dl) 4.29 ± 0.45 4.43 ± 0.33 4.19 ± 0.43 <.0001 
Creatinine (mg/dl) 0.87 ± 0.25 0.86 ± 0.21 0.87 ± 0.29 0.75 
WBC (cells/cumm) 7.21 ± 2.88 7.41 ± 3.08 7.19 ± 2.55 0.58 
Hgb (g/dl) 14.05 ± 1.40 14.24 ± 1.18 14.04 ± 1.52 0.26 
PLT (cells/cumm) 234.07 ± 93.35 261.94 ± 73.70 203.01 ± 103.46 <0.0001 
INR 1.16 ± 0.27 1.08 ± 0.07 1.19 ± 0.24 <0.0001 
Triglyceride (mg/dl) ^ 164.13 ± 84.40 167.35 ± 86.79 166.36 ± 83.46 0.94 
Cholesterol (mg/dl) ^ 171.52 ± 42.21 175.14 ± 42.45 166.39 ± 37.93 0.18 
HDL (mg/dl) ^ 42.75 ± 12.56 42.46 ± 12.73 43.72 ± 12.52 0.53 
LDL (mg/dl) ^ 104.49 ± 57.77 106.11 ± 53.40 102.16 ± 65.43 0.67 
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SF-36 scales  
Physical Component 
Summary Score (PCS) 40.52 ± 11.35 43.91 ± 10.21 
35.92 ± 11.2 < 0.0001 
Physical Functioning 68.34 ± 27.81 76.13 ± 24.96 59.74 ± 27.74 < 0.0001 
Role Limitations due to 
Physical Health  58.06 ± 43.54 69.64 ± 41.41 
43.07 ± 41.70 < 0.0001 
Pain 58.32 ± 26.00 62.16 ± 26.07 53.36 ± 24.22 0.005 
General Health 50.93 ± 22.46 56.10 ± 21.82 43.00 ± 20.65 < 0.0001 
Mental Component 
Summary Score (MCS) 48.51 ± 10.66 48.40 ± 10.30 
48.55 ± 10.99 0.91 
Emotional Well-being  71.23 ± 19.27 71.47 ± 20.12 71.21 ± 18.55 0.91 
Role Limitations due to 
Emotional Problems 74.26 ± 39.01 78.06 ± 37.14 
69.64 ± 41.39 0.07 
Energy/Fatigue 43.22 ± 22.50 45.97 ± 22.37 38.23 ± 22.35 0.005 
Social Functioning 75.40 ± 27.50 78.05 ± 27.58 73.14 ± 25.82 0.13 
 
Abbreviations: Body Mass Index (BMI); Alanine aminotransferase (ALT); Aspartate 
aminotransferase (AST); Alkaline Phosphatase (ALP); White Blood Cells (WBC); Hemoglobin 
(Hgb); Platelet (PLT); International Ionizes Ratio (INR); High Density Cholesterol (HDL): Low 
Density Cholesterol (LDL) 
¶Comparing NAFLD patients with and without advanced fibrosis.  
*Vibration Controlled Transient Elastography data was available in 299 participants.  
#Mean ± SD for Liver Stiffness Measurement was: Overall = 13.63 ± 13.09; Non-advanced fibrosis 
= 6.85 ± 2.27 and Advanced fibrosis = 24.75 ± 14.04. 
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Table 2: Correlation between body composition parameters with the physical scale of SF-36 (N=274) 
 
*PCS is a summary measure of physical function, role limitations due to physical function, pain and general health. MCS is a 
summary measure of emotional function, role limitations due to emotional problems, social function, energy/fatigue.  
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p-value 0.0220 <0.0001 0.004 <0.0001 <0.0001 0.3741 0.176 0.088 0.018 <0.0001 
Percent 



























































































p-value 0.0220 0.0004 0.016 0.060 0.182 0.0095 0.012 0.002 0.0007 0.149 
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Table 3:  Clinical factors associated with Physical Function Scale of SF-36 in the 
NAFLD cohort ¥ 
 
 Univariate Analysis  Multivariable Analysis *# 
Variables  Correlation 
Coefficient (95% CI) p-value 
Correlation 
Coefficient (95% CI) p-value 
Age  -0.60 (-0.81 to -0.38) <0.0001 -0.22 (-0.46 to 0.02) 0.07 
Gender: Male 10.04 (4.10 to 15.98) <0.001 -6.47 (-17.5 to 4.6) 0.2 
Race: Caucasian vs rest -9.90 (-24.74 to 4.94) 0.19   
BMI -1.00 (-1.40 to -0.60) <0.0001 -1.38 (-1.9 to -0.85) <0.0001 
Lean Body Mass 0.36 (0.11 to 0.60) 0.004 0.82 (0.3 to 1.27) 0.0004 
Type 2 Diabetes mellitus - 9.19 (-15.32 to -3.04) 0.003 -6.5 (-12.77 to -0.23) 0.04 
Dyslipidemia 3.63(-2.61 to 9.88 ) 0.25   
Hypertension -7.81 (-14.00 to -1.63) 0.01   
Alanine aminotransferase 0.23 (0.15 to 0.32) <0.0001 0.16 (0.08 to 0.24) 0.0001 
Aspartate 
aminotransferase 0.11 (-0.03 to 0.25) 0.12   
Liver Stiffness 
Measurement (KPa) -0.54 (-0.79 to -0.29) <0.0001 -0.37 (-0.61 to -0.12) 0.002 
Histopathology: Fibrosis   -6.64 (-9.97 to -3.31) <0.0001   
Histopathology: Steatosis -0.43(-6.17 to 5.32) 0.89   
Histopathology: Ballooned 
Hepatocytes* -9.10 (-15.33 to -2.86) 0.004   
Histopathology: Lobular 
Inflammation   
2.78 (-4.92 to 10.47) 0.48   
 
 Abbreviations: Body Mass Index: BMI 
 ¥Values expressed as β-coefficients (95% CI) 
*Variables with excessive missingness rate were not included in multivariable analysis. 
#Multivariable model was based on an available sample size of 248 using listwise deletion due 
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Table 4:  Differences in SF-36 scales in individuals with and without advanced 
fibrosis based on Transient elastography. ¥ 
 
SF-36 Scales  Liver 
Stiffness 
Measurement 





≥ 12.1KPa  
(n= 102) 
P-value  
Physical Functioning  76.13 ± 24.96   59.74 ± 27.74  <.0001 
Role Limitations due to Physical 
Health   69.64 ± 41.41   43.07 ± 41.70  <.0001 
Emotional Well-being  62.16 ± 26.07   53.36 ± 24.22  0.005 
Role Limitations due to 
Emotional Problems  56.10 ± 21.82   43.00 ± 20.65  <.0001 
Energy/Fatigue  45.97 ± 22.37   38.23 ± 22.35  0.005 
Social Functioning  78.05 ± 27.58   73.14 ± 25.82  0.139 
Pain  78.06 ± 37.14   69.64 ± 41.39  0.076 
General Health  71.47 ± 20.12   71.21 ± 18.55  0.912 
¥Values are shown as means ± standard deviation unless otherwise specified.  
  
   Samala et al. (21) 
 
 
Table 5: Factors associated with SF-36 in the NAFLD without advanced fibrosis ¥ 
 
 Univariate Analysis  Multivariable  Analysis *# 
Variables  B-coefficient  p-value  B-coefficient  p-
value 
Age -0.38 (-0.64 to -0.12) 0.005 -0.24 (-0.50 to 0.03) 0.09 
Gender 14.94 (8.14 to 21.76) <0.0001 -2.14 (-15.04 to 
10.76) 
0.74 
Race: Caucasian vs rest 0.76 (-13.78 to 15.30) 0.92   
BMI -0.77 (-1.27 to 0.27) 0.002 -1.13 (-1.76 to -0.50) <0.001 
Lean Body Mass 0.57 (0.35 to 1.0) <0.0001 0.71 (0.19 to 1.23) 0.007 
DM-2 -4.20 (-11.51 to -3.11) 0.26   
Dyslipidemia -1.32 (-8.51 to 5.87) 0.13   
Hypertension -4.44 (-11.54 to 2.66) 0.22   
ALT  0.17 (0.07 to 0.28) 0.001 0.13 (0.04 to 0.24) 0.007 
AST 0.08 (-0.08 to 0.24) 0.34   
Liver Stiffness 
Measurement (K Pa) 
0.006 (-5.47 to 5.47) 1.00   
Histopathology: Fibrosis 0.58 (-0.96 to 2.12) 0.46   
Histopathology: Steatosis  0.75 (-6.45 to 7.94) 0.84   
Histopathology: Ballooned 
Hepatocytes -5.92 (-13.32 to 1.48) 0.12   
Histopathology: Lobular 
Inflammation -1.34 (5.08 to -11.31) 0.79   
 
Abbreviations: Body Mass Index: BMI 
¥Values expressed as β-coefficients (95% CI) 
*Variables with excessive missingness rate were not included in multivariable analysis. 
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Need to Know 
Background: Patients with nonalcoholic fatty liver disease (NAFLD) might have reduced 
quality of life (QOL). 
Findings: Patients with NAFLD, even those without advanced fibrosis, have lower QOL 
than controls. Body composition associates with QOL in patients with NAFLD.  
Implications for patient care: Improving body composition might increase QOL for 
patients with NAFLD. 
 
